drugset
drugset / Trial / NCT04656431

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma

NCT04656431 ↗

Phase 1 Recruiting 26 enrolled James Rubenstein National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This phase I trial evaluates the feasibility of using hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing patients with primary central nervous system lymphoma. This trial aims to see whether MRI using hyperpolarized carbon-13 pyruvate is safe and useful for detecting central nervous system lymphoma and evaluating response to treatment.

Timeline

Start
2021-06-29
Primary completion
2027-03-31
Completion
2027-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Hyperpolarized 13C-Pyruvate Diagnostic / imaging agent — Intravenous

Indications

primary central nervous system lymphoma